Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM FL
NCT06313996Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Primary completion
- Oct 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 3 trial of lisocabtagene maraleucel in follicular lymphoma (FL), sponsored by Bristol Myers Squibb. Planned start Mar 2024; status: withdrawn.
02
Drugs
lisocabtagene maraleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06313996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313996.